SCHEMBL5481025

SCHEMBL5481025

N#Cc1cccnc1N1CCN(C(=O)/C=C/c2cccc(Cl)c2F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.55
MAPT P10636 3/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
KDM4E B2RXH2 4/20 0.48
MALT1 Q9UDY8 1/20 0.48
DRD2 P14416 2/20 0.48
HTR2A P28223 2/20 0.48
RECQL P46063 1/20 0.47
PANK3 Q9H999 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
HTR1A P08908 1/20 0.46
HTR7 P34969 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
HDAC2 Q92769 2/20 0.45
GAA P10253 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5481028 1.00 ENPP2 (0.55) ENPP2MAPTALDH1A1HPGDKDM4E
SCHEMBL5486932 0.82 LMNA (0.54) MAPTALDH1A1HPGDL3MBTL1
SCHEMBL5486927 0.82 LMNA (0.54) MAPTALDH1A1HPGDL3MBTL1
SCHEMBL5486563 0.80 L3MBTL1 (0.69) ENPP2MAPTALDH1A1KDM4ERECQL
SCHEMBL5486556 0.80 L3MBTL1 (0.69) ENPP2MAPTALDH1A1KDM4ERECQL
SCHEMBL5475932 0.80 ENPP2 (0.59) ENPP2MAPTALDH1A1HPGDKDM4E
SCHEMBL5475934 0.80 ENPP2 (0.59) ENPP2MAPTALDH1A1HPGDKDM4E
SCHEMBL5486984 0.77 L3MBTL1 (0.53) ENPP2MAPTALDH1A1KDM4ERECQL
SCHEMBL5486990 0.77 L3MBTL1 (0.53) ENPP2MAPTALDH1A1KDM4ERECQL
SCHEMBL5483936 0.77 LMNA (0.57) ENPP2MAPTALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US claimed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists GRM5, GRM1, GRM3 ENPP2 2635/4885MAPT 1549/4885ALDH1A1 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.